相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Results of the Surveillance of Tedizolid Activity and Resistance Program: in vitro susceptibility of Gram-positive pathogens collected in 2011 and 2012 from the United States and Europe
Daniel F. Sahm et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2015)
Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial
Gregory J. Moran et al.
LANCET INFECTIOUS DISEASES (2014)
Antimicrobial-Resistant Pathogens Associated with Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010
Dawn M. Sievert et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2013)
Tedizolid Phosphate vs Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infections The ESTABLISH-1 Randomized Trial
Philippe Prokocimer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
The Clinical Significance of Vancomycin Minimum Inhibitory Concentration in Staphylococcus aureus Infections: A Systematic Review and Meta-analysis
S. J. van Hal et al.
CLINICAL INFECTIOUS DISEASES (2012)
In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci
Iciar Rodriguez-Avial et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Daptomycin Nonsusceptible Enterococci: An Emerging Challenge for Clinicians
Theodoros Kelesidis et al.
CLINICAL INFECTIOUS DISEASES (2011)
Comparative In Vitro Antimicrobial Activities of Torezolid (TR-700), the Active Moiety of a New Oxazolidinone, Torezolid Phosphate (TR-701), Determination of Tentative Disk Diffusion Interpretive Criteria, and Quality Control Ranges
Steven D. Brown et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
In Vitro Activity of TR-700, the Active Ingredient of the Antibacterial Prodrug TR-701, a Novel Oxazolidinone Antibacterial Agent
Ronda Schaadt et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci
David M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals
Helio S. Sader et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Heterogeneous Vancomycin-Intermediate Susceptibility Phenotype in Bloodstream Methicillin-Resistant Staphylococcus aureus Isolates from an International Cohort of Patients with Infective Endocarditis: Prevalence, Genotype, and Clinical Significance
In-Gyu Bae et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
In Vitro Activity of TR-700, the Antibacterial Moiety of the Prodrug TR-701, against Linezolid-Resistant Strains
K. J. Shaw et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides
Mandy Wootton et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2007)
Distribution of florfenicol resistance genes fexA and cfr among chloramphenicol-resistant Staphylococcus isolates
C Kehrenberg et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001
SK Fridkin et al.
CLINICAL INFECTIOUS DISEASES (2003)
分享论文
